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Abstract
Purpose Transcutaneous electrical nerve stimulation (TENS) is a treatment option for cancer pain, but the evidence is inconclu-
sive. We aimed to evaluate the efficacy and safety of TENS.
Methods A blinded, randomized, sham-controlled pilot cross-over trial (NCT02655289) was conducted on an inpatient specialist
palliative care ward. We included adult inpatients with cancer pain ≥ 3 on an 11-point numerical rating scale (NRS). Intensity-
modulated high TENS (IMT) was compared with placebo TENS (PBT). Patients used both modes according to their preferred
application scheme during 24 h with a 24-h washout phase. The primary outcome was change in average pain intensity on the
NRS during the preceding 24 h. Responders were patients with at least a “slight improvement.”
Results Of 632 patients screened, 25were randomized (sequence IMT-PBT= 13 and PBT-IMT= 12). Finally, 11 patients in IMT-PBT
and 9 in PBT-IMT completed the study (N = 20). The primary outcome did not differ between groups (IMT minus PBT: − 0.2, 95%
confidence interval − 0.9 to 0.6). However, responder rates were higher in IMT (17/20 [85%] vs. 10/20 [50%], p = 0.0428). Two
patients experienced an uncomfortable feeling caused by the current, one after IMTand one after PBT. Seven patients (35%) desired a
TENS prescription. Women and patients with incident pain were most likely to benefit from TENS.
Conclusion TENSwas safe, but IMTwas unlikely to offer more analgesic effects than PBT. Even thoughmany patients desired a
TENS prescription, 50% still reported at least “slight pain relief” from PBT. Differences for gender and incident pain aspects
demand future trials.
Keywords Palliative care . Cancer pain . Non-pharmacological . Transcutaneous electrical nerve stimulation . Complementary
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Introduction
Cancer pain is a leading symptom on palliative care units (ca.
80% of patients) [1, 2]. As an adjunct to pharmacological
cancer pain management, transcutaneous electrical nerve
stimulation (TENS) is a safe, non-invasive, and inexpensive
non-pharmacological option for pain treatment [3–5]. TENS
is usually applied at the site of pain, where it stimulates large
diameter (A-β) afferent fibers, which leads to a decreased
activity of transmission cells and subsequently to reduced per-
ception of pain according to the Gate-Control-Theory [6].
Though TENS is recommended in most palliative care and
cancer pain textbooks [3, 4], controlled trials from a palliative
care setting are lacking, what may be due to multimorbidity,
recruitment barriers, high attrition rates, and general ethical diffi-
culties [7]. In a Cochrane Review on TENS for cancer pain in
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adult patients, only three RCTswere identified [8]. Varying study
designs, TENS modes, and outcome measures across studies as
well as small sample sizes led to inconclusive results [9–11].
Therefore, the primary aim was to evaluate efficacy and
safety of TENS in addition to standard care for advanced
cancer pain patients. The secondary aim of this study was
the exploratory identification of subgroups that do or do not
benefit from TENS.
Materials and methods
Study design and setting
This was a blinded, randomized, sham-controlled pilot cross-
over trial (DRKS00007990; ClinicalTrials.gov Identifier
NCT02655289). Patients were recruited from the inpatient
specialist palliative care ward and the acute pain service of
the University Medical Center Freiburg, Germany.
The study was approved by the local ethics committee in
2015. We report this manuscript in accordance with the
Consolidated Standards of Reporting Trials (CONSORT)
Statement’s extension for non-pharmacological treatments
(NPTs) (Online Resource 1) [12] and the Template for
Intervention Description and Replication (TIDieR) checklist
(Online Resource 2) [13].
Participants
We included adult inpatients ≥ 18 years with cancer and pain
≥ 3 on an 11-point numerical rating scale (NRS, 0 = no pain;
10 = pain as bad as you can imagine) in the preceding 24 h.
Pain could have been caused by the tumor itself (cancer pain),
cancer-directed therapy, or by an association with the tumor,
e.g., being bedridden or daily activities. Patients had to have
received specialist palliative care for at least 24 h in the inpa-
tient palliative care ward or by the acute pain service. There
were no limitations concerning tumor site and type of cancer
pain (neuropathic and nociceptive pain).
The exclusion criteria were verbal or cognitive inability to use
TENS or to answer the questionnaire, high probability of dying
within the next week according to the treating physician, and
pain that was not directly or indirectly related to the tumor (i.e.,
chronic low back pain). In addition, we used the following TENS
contraindications [4, 14]: electronic implants like pacemakers,
metal implant on electrode site, arrhythmia, pregnancy, epilepsy,
dermatological conditions or frail skin on electrode site, and his-
tory of allergy regarding electrodes or patches.
Intervention: intensity-modulated high TENS
A dual channel TENS device (ARTROSTIM® SELECT™,
ORMED) was used at the site of pain in the intervention
(IMT) and placebo TENS (PBT) phase. Patients were
instructed by an experienced researcher who received training
and supervision of a senior physician. The intervention used
intensity-modulated TENS (IMT) with 100 Hz. The patients
were advised to choose a “strong but comfortable” intensity
[5, 15] and the intensity was modulated automatically with a
decrease of 40% every 0.5 s in order to prevent habituation
[16].
IMT and PBTwere used by patients individually, i.e., they
were free to turn TENS on or off as they pleased, according to
their own perceived benefit.
Comparison: Placebo TENS
PBT, or sham-controlled TENS, was based on the continuous
mode with 100 Hz and a fixed intensity, which was either
slightly or not perceptible at all. For the sake of adequate
blinding, we instructed the patients that two active TENS
modes were compared. Patients were informed that the
TENS device could be turned on according to individual
needs and that the sensory threshold would probably not be
reached in this TENS mode. The TENS device was activated
for PBTwith an intensity that was mostly perceptible for a few
seconds and then fell below the sensory threshold through
habituation. The display and flashing light of the device in
the PBT mode looked and behaved exactly as in the IMT
mode [17].
Outcomes
Most outcomes were based on the Brief Pain Inventory (BPI)
[18, 19] and were chosen with consideration to recommenda-
tions for pain assessment [17, 20].
The primary outcome was change of mean pain intensity in
the preceding 24 h, measured on an 11-point NRS before and
after the 24-h IMTor PBT phase and after the flexible follow-
up.
Secondary outcomes of the BPI over the 24 h period in-
cluded change of worst pain intensity, change of least pain
intensity, and BPI items that may have been affected by pain:
general activity, mood, walking ability, normal work, relations
with other people, sleep, and enjoyment of life. Some out-
comes were measured on other scales: change of pain percep-
tion during TENS application on a 7-point verbal rating scale
(VRS), number and percentage of responders defined as pa-
tients with at least a “slight improvement” on the
abovementioned 7-point VRS. Question 30 from the
European Organization for Research and Treatment of
Cancer quality of life questionnaire C30 (EORTC QLQ-
C30) [21] was used to assess quality of life.
Medication with an influence on pain (opioids, non-
opioids, antidepressants, anticonvulsants) was documented
at baseline and during the study, i.e., if a new drug was added
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or removed, or if the dose of a drugwas increased or decreased
by > 50% [22]. Furthermore, the oral morphine equivalent
dose (MED) was calculated. Pain classification was assessed
with the Edmonton Classification System for Cancer Pain [23]
and the Douleur Neuropathique en 4 Questions (DN4) [24].
Study procedure
The patients were screened by treating physicians in the inpa-
tient palliative care ward and the acute pain service. Eligible
patients were contacted by the study team to obtain informed
consent for study participation. A senior physician was re-
sponsible for the randomization list, enabled a concealed cen-
tral allocation, and patients were directly randomized after
giving informed consent. Randomization was performed ac-
cording to a random, computer-generated list with an alloca-
tion ratio of 1:1.
The senior physician was not involved in the provision of
the intervention or data assessment. TENS was started imme-
diately after allocation to the sequence, and patients were
instructed that two active TENS modes were compared in this
study.
Patients, researchers, the outcome assessor, and the biome-
trician were blinded concerning the mode of intervention.
Thus, the researcher placed the electrodes without knowing
the TENS mode. TENS was subsequently activated (IMT or
PBT) by a non-blinded treating physician who was not in-
volved in the data collection, data analysis, or the preparation
of the manuscript. Patients were instructed not to tell anything
about their perceptions of the TENS mode to the research
team and had to turn off the TENS device during answering
the questionnaire.
Patients used the first TENS mode during the first 24-h
phase (period 1). After the 24 h washout phase, the patient
crossed over to the other TENSmode for another 24 h (period
2). After the main part of the study (period 1 and period 2),
patients could decide whether to continue with one of the
TENS modes (IMT or PBT) for a flexible short-term follow-
up or to stop the study (see study design: Online Resource 3).
Statistical analysis
We aimed to include 20 patients in this pilot trial to assess the
effects and safety (primary aim), and gather valuable informa-
tion for a fully poweredmulticenter study. This cross-over trial
was analyzed according the recommendations by Wellek and
Blettner [25] and Li et al. [26]. Unpaired t tests of the within-
subject sums of the result from both periods were used to
check carry-over effects (p ≥ 0.05: carry-over effect is negligi-
ble) [25]. Paired t tests were calculated for within-subject dif-
ferences of change scores from both periods (t2 minus t1, or t4
minus t3, see Online Resource 3). As sensitivity analysis,
paired t tests were also calculated for within-subject
differences of post treatment scores from both periods (t2,
t4), according to the recommendations by Li et al. [26].
Numbers of responders were compared with the help of the
chi-squared test.
As subgroup analysis (secondary aim), we explored charac-
teristics from patients that benefited or did not benefit from
TENS regarding average pain intensity in the preceding 24 h.
Benefit was defined as difference of more than minus one for
change scores (primary outcome) and post treatment scores
when subtracting IMTminus PBT, and/or change scores within
groups (IMT, PBT) of more than minus one on the NRS [27].
Patients with complete data for period 1 and period 2 were
analyzed per-protocol [28] and were evaluated irrespective of
how often or how long they used the TENS modes.
All tests for the secondary outcomes were exploratory. The
tests were performed two-tailed using an alpha level of 0.05.
The statistical analysis was performed using R (RStudio
Version 3.4.2) [29].
Results
Screening and patient inclusion
Participants were recruited from February 2016 to February
2018.We screened 632 patients on the inpatient palliative care
ward (see Fig. 1). Most of the patients (591/632, 93.5%) were
not eligible (Fig. 1). Twenty-five of 41 (61.0%) eligible pa-
tients were randomized. Eleven patients in IMT-PBT and 9 in
PBT-IMT completed the study (N = 20).
The dropout analysis is presented in detail in Online
Resource 4. It shows that six of the 26 recruited patients
(23.1%) were dropouts, one of them dropped out after signing
informed consent but before randomization (see Fig. 1). These
dropped out patients tended to have a higher Eastern
Cooperative Oncology Group (ECOG) level and higher aver-
age pain levels before receiving PBT: 3.35 (standard deviation
[SD] 1.35) vs. 5.25 (SD 0.5). The other variables were, for the
most part, balanced.
Most patients (15/20, 75%) stopped the study after com-
pleting both sequences and were not available for the short-
term follow-up, e.g., because of the burden in using TENS
(5/15, 33%) or no perceived effect (3/15, 20%) (see Online
Resource 5).
Baseline characteristics
Table 1 shows the baseline characteristics in both sequences.
Most characteristics were well balanced. Slight differences
between both sequences were observed in cancer entity,
ECOG, and DN4. Average pain at baseline was lower in the
IMT-PBT than in the PBT-IMTsequence and, within the IMT-
PBT sequence, lower in PBT than in IMT (see Table 1).
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Regular medication intake before randomization interven-
tion was comparable between sequences (Online Resource 6).
The oral MED per day had slightly higher means and SDs in
the IMT-PBT sequence. Opioid, non-opioid, antidepressant,
and anticonvulsant intake was equally distributed between
IMT-PBT and PBT-IMT. None of these drugs were decreased
by > 50% of the dose or removed during the trial. In IMT,
increasing or adding drugs was not necessary. In PBT, some
drugs had to be added or increased by > 50% of the dose: non-
opioid 2/20 (10%), antidepressant 1/20 (5%), and anticonvul-
sant 1/20 (5%).
Duration of TENS use
In sequence IMT-PBT, patients used TENS for 10.6 h (SD
8.3) in IMTand for 5.7 h (SD 5.0) in PBT based on the record
from the TENS device. In contrast, the TENS use in sequence
PBT-IMT was 7.1 h (SD 6.3) in IMT and 8.4 h (SD 6.2) in
PBT. In total, TENS was used for 9.1 h (SD 7.5) in IMT and
for 7.0 h (SD 5.6) in PBT during the 24-h period (p = 0.3340;
n = 17; three missing values) (Online Resource 7).
Difference between groups
Table 2 shows the change scores in periods, sequences, and
the total for analyzing differences between the IMT and PBT
phase in the primary and secondary outcomes.
The differences of IMTminus PBT for each sequence were
rather small and none of them were statistically significant in
this pilot trial. The results of the change scores were consistent
with the sensitivity analysis of post treatment scores (Online
Resource 8) [26].
Figure 2a and b illustrates each participant’s change score
and post treatment score, respectively, that were used to com-
pare IMT and PBT (negative values favor IMT).
The change of pain perception during the TENS applica-
tion is shown in Table 3. Seventeen out of 20 patients (85%)
had at least a “slight improvement” on the 7-point VRS (re-
sponder criterion) during IMT and 10/20 (50%) during the
PBT phase (p = 0.0428).
Difference within groups
The analysis of changes within IMT indicated that patients
experienced a decrease in average pain, worst pain, least pain,
mood, walking ability, and relations (Table 4). In PBT, compa-
rable changes were observed for average pain and worst pain
but not for any of the other outcomes (Online Resource 9).
Figure 2 gives an overview of the change within groups for
the primary outcome. Both IMT (Fig. 2c) and PBT (Fig. 2d)
clearly included more negative change scores with slightly
more decrease in average pain for IMT.
Safety: TENS-related adverse events
One out of 20 (5%) patients perceived the electric current as
uncomfortable after the IMT phase and 1/20 (5%) after the
PBT phase. No other TENS-related adverse events were re-
ported. Four patients (20%) generally criticized that cables
were impractical and one (5%) patient felt disturbed by the
electrodes.
After testing both TENS modes, 7/20 (35%) patients re-
quested a prescription for the TENS device in order to use
TENS after discharge.
Explorative subgroup analysis
Online Resources 10, 11, 12, and 13 show the core outcomes
for mean pain intensity (see Fig. 2), which were analyzed with
regard to the patients’ benefit. Four patients in the change
score comparison (Online Resource 10), one patient in the
post treatment comparison (Online Resource 11), seven pa-
tients in the change within IMT comparison (Online Resource
12), and five patients in the change within PBT comparison
(Online Resource 13) experienced a benefit, defined as differ-
ence or change of more than minus one on the NRS (see also
Fig. 2). Taking the baseline values in Table 1 into account,
descriptive comparisons indicated that females and patients
suffering from incident pain were probably more likely to
benefit from IMT although the sample sizes of these compar-
isons were very small (Online Resource 10, Online Resource
12). The explorative subgroup analysis did not indicate differ-
ences between patients with neuropathic and non-neuropathic
pain.
Discussion
Summary of main findings
With regard to change in average pain intensity (primary out-
come), we observed no differences between IMT and PBT.
However, results indicated higher responder rates for IMT as
secondary outcome. TENS was safe and well accepted.
Difference between groups
There were no statistically significant differences between
groups. These findings are supported by other RCTs, which
evaluated TENS in cancer patients [9–11]. However, neither
our study nor the other RCTs were powered to detect small
effects between groups. In contrast, a recent, powered cross-
over RCT with 40 head and neck cancer patients identified
clinically relevant effects favoring active TENS compared
with PBT and no TENS for resting pain [27, 30–32]. In this
trial, the outcomes were assessed before and directly after
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30 min of TENS. Change scores were compared among three
TENS conditions (active TENS with 125 Hz, PBT, no TENS)
and seven outcomes resulting in 21 statistical tests, which
raises the question of a multiple testing problem in this anal-
ysis [33].
Interestingly, our results indicate that IMT had more re-
sponders than PBTas measured on the 7-point VRS (respond-
er criterion: at least a “slight improvement”) for change of pain
perception during TENS application. This important finding is
strengthened by another cross-over RCT, in which the authors
also observed a difference between active TENS and PBT on
the VRS but not on the NRS scale [9]. Therefore, a 7-point
VRS for pain relief might be more responsive than an 11-point
NRS for assessing TENS in short period interventions [9].
Difference within groups
In IMT, the items worst pain, mood, walking ability, and re-
lations showed a mean change of one or more on an 11-point
NRS in the IMT phase, which was suggested as clinically
relevant [30]. Additionally, the mean changes of IMT in least
pain, mood, walking ability, and relations may also be clini-
cally relevant for individual patients, i.e., a change of two
points or more on an 11-point NRS or a pain relief of 33%
ormore [27]. The change in walking ability for IMTunderpins
the idea that TENS may be helpful to reduce movement-
related pain [9, 15].
For PBT, only changes in average pain and worst pain were
observed. Similar to IMT, the changes in average pain were
slightly below the threshold of clinical relevance as explained
above [27, 30]. However, the change of − 1.6 (95%CI − 2.7 to
− 0.4) in worst pain in the PBT phase can be considered clin-
ically relevant [30].
Comparable changes within groups were also reported in
other RCTs for average pain and worst pain [11], pain at rest
[9, 31] or at movement [9], and fatigue [31].
The results underline that different outcome measures
should be assessed since reduced pain perception could result
in increased activity levels implying changes in physical func-
tion and psycho-social outcomes [10, 15].
TENS-related adverse events
With regard to safety, IMTwas well accepted and safe in this
study. These results are comparable with the analysis of an-
other RCT [9]. The six dropped out patients tended to have a
higher ECOG level and higher average pain levels before
receiving PBT. The other variables were balanced or hard to
judge because of the low number of dropouts. The safety of
TENS was not explicitly measured in some RCTs [10, 11, 31]
but authors referred to TENS as safe method. A usability
problem rather than a safety problemwas the fact that the main
reason for stopping the study after period 2 was the burden in
using TENS (5/15, 33%), e.g., because of the disturbing ca-
bles of the device (see Online Resource 5 for further reasons).
Fig. 1 Flow diagram
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Table 1 Baseline characteristics
Sequence IMT-PBT: N = 11 Sequence PBT-IMT: N = 9
Age, mean (SD) 58.3 (16.2) 59.2 (9.4)
Sex
Male 4 (36.4%) 4 (44.4%)
Female 7 (63.6%) 5 (55.6%)
BMI, mean (SD) 23.6 (6.5) 23.5 (4.1)
ECOG
1 0 (0.0%) 0 (0.0%)
2 7 (63.6%) 3 (33.3%)
3 4 (36.4%) 6 (66.7%)
4 0 (0.0%) 0 (0.0%)
Primary tumor
Lung-Ca 3 (27.3%) 2 (22.2%)
Pancreas-Ca 2 (18.2%) 0 (0.0%)
Mamma-Ca 0 (0.0%) 1 (11.1%)
Prostate-Ca 0 (0.0%) 1 (11.1%)
Rectum-Ca 1 (9.1%) 0 (0.0%)
Miscellaneous 5 (45.5%) 5 (55.6%)
TENS position
Lower limb 1 (9.1%) 0 (0.0%)
Lumbar spine 3 (27.3%) 2 (22.2%)
Pelvis 2 (18.2%) 2 (22.2%)
Ribs 4 (36.4%) 1 (11.1%)
Scapula 0 (0.0%) 1 (11.1%)
Thoracic spine 1 (9.1%) 3 (33.3%)
Radiation (not in TENS area)
Yes 2 (18.2%) 2 (22.2%)
No 9 (81.8%) 7 (77.8%)
DN4 score
DN4 < 4 8 (72.7%) 4 (44.4%)
DN4 ≥ 4 3 (27.3%) 5 (55.6%)
ECP mechanism of pain
Nociceptive: visceral and/or bone or soft tissue 6 (54.5%) 4 (44.4%)
Neuropathic with or without nociceptive pain 5 (45.5%) 5 (55.6%)
ECP incident pain
Yes 10 (90.9%) 7 (77.8%)
No 1 (9.1%) 2 (22.2%)
ECP psychological distress
Yes 9 (81.8%) 7 (77.8%)
No 2 (18.2%) 1 (11.1%)
Insufficient information to classify 0 (0.0%) 1 (11.1%)
Non-physical effects on pain (“total pain”)
No effect 1 (9.1%) 0 (0.0%)
Small effect 6 (54.5%) 4 (44.4%)
Moderate effect 3 (27.3%) 2 (22.2%)
Large effect 1 (9.1%) 3 (33.3%)
Large effect 0 (0.0%) 0 (0.0%)
Average pain before treatment IMT, mean (SD) 3.5 (1.0) 4.2 (0.8)
Average pain before treatment PBT, mean (SD) 2.6 (1.2) 4.2 (1.0)
BMI, body mass index; DN4, Douleur Neuropathique en 4 Questions; ECOG, Eastern Cooperative Oncology Group; ECP, Edmonton Classification
System for Cancer Pain; IMT, intensity-modulated high TENS; NRS, numerical rating scale; PBT, placebo TENS; SD, standard deviation; TENS,
transcutaneous electrical nerve stimulation
DN4 score: range 0–10: higher score = greater neuropathic pain (≥ 4 cutoff value for neuropathic pain)
ECOG: range 0–5. 0 = Fully active, able to carry on all pre-disease performance without restriction; 1 = restricted in physically strenuous activity but
ambulatory and able to carry out work of a light or sedentary nature, e.g., light house work, office work; 2 = ambulatory and capable of all self-care but
unable to carry out any work activities, up and about more than 50% of waking hours; 3 = capable of only limited self-care, confined to bed or chair more
than 50% of waking hours; 4 = completely disabled, cannot carry on any self-care, totally confined to bed or chair; 5 = dead (Oken et al., 1982)
NRS for average pain: 0 = no pain or no interference; 10 = worst imaginable pain or maximum interference
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Gender aspects and incident pain
Among all benefit subgroup analyses, we believe that two
findings are noteworthy even though the results were descrip-
tive and the sample size was very small.
Gender In palliative care and in the field of cancer pain
management, gender issues are currently becoming in-
creasingly recognized and future research in this area is
advocated [34–36]. Interestingly, in our trial, women were
more likely to report improvement from TENS. This could
be a result of recently discussed sex differences regarding
testosterone and estrogen levels as well as T cells and im-
mune cells and their role in pain perception. However,
most findings were based on animal models [37]. To the
best of our knowledge, we are unaware of previous TENS
RCTs in cancer pain reporting a gender differences in ben-
efit subgroup analysis.
Incident pain In the field of cancer pain, incident cancer pain
has been identified as a condition with room for improvement
in terms of the available treatment options [38]. Therefore, it
should be noted that in our study, patients with incident cancer
pain were more likely to experience benefit under TENS,
which has not been assessed in previous TENS trials in palli-
ative care [8]. A reason for this finding might be that demon-
strating a change was easier in patients with increased pain
scores than in the comparatively low baseline pain scores of
patients without incident pain [9].
Strengths
The strength of this study is the cross-over design that allowed
patients to be their own control and have a balance of covar-
iates [9]. The generalizability can be considered high because
of the wide inclusion criteria, no artificial changes in patients’
medication plans, and the possibility of an individual use of
Table 2 Differences between groups. Change scores in periods, sequences, and total (IMT-PBT: N = 11; PBT-IMT: N = 9; total: N = 20)
Outcome Sequence Period 1 Period 2 IMT minus PBT Total IMT minus PBT p value*
Mean (SD) Mean (SD) Mean of differences (SD) Mean of differences (95% CI)
Average pain IMT-PBT − 0.8 (1.0) − 0.4 (1.0) − 0.5 (1.4) − 0.2 (− 0.9 to 0.6) 0.6590
NRS: 0–10 PBT-IMT − 1.2 (1.5) − 1.0 (1.4) 0.2 (1.6)
Worst pain IMT-PBT − 1.4 (1.7) − 1.4 (2.1) 0.0 (2.6) 0.3 (− 1.1 to 1.6) 0.7125
NRS: 0–10 PBT-IMT − 1.8 (3.1) − 1.2 (1.3) 0.6 (3.6)
Least pain IMT-PBT − 0.5 (1.1) − 0.4 (1.2) − 0.1 (2.0) − 0.2 (− 1.1 to 0.7) 0.6295
NRS: 0–10 PBT-IMT − 0.7 (1.4) − 1.0 (0.9) − 0.3 (1.7)
Quality of life IMT-PBT 0.7 (1.4) 0.1 (1.3) 0.6 (2.0) − 0.1 (− 1.0 to 0.8) 0.8252
Scale: 1–7 PBT-IMT 0.9 (1.4) − 0.1 (1.2) − 1.0 (1.7)
General activity IMT-PBT − 1.0 (3.2) − 1.5 (2.6) 0.5 (4.5) 0.0 (− 2.2 to 2.2) 1.0000
NRS: 0–10 PBT-IMT − 1.2 (4.0) − 1.9 (2.9) − 0.7 (5.1)
Mood IMT-PBT 0.0 (3.3) − 0.5 (2.9) 0.5 (3.9) 0.3 (− 1.5 to 2.1) 0.7351
NRS: 0–10 PBT-IMT − 2.1 (3.9) − 2.0 (1.7) 0.1 (4.1)
Walking ability IMT-PBT − 1.8 (3.9) 0.4 (2.1) − 2.2 (4.5) − 1.0 (− 2.9 to 1.0) 0.3229
NRS: 0–10 PBT-IMT − 2.3 (3.7) − 1.8 (2.2) 0.6 (3.5)
Normal work IMT-PBT − 2.7 (3.6) 0.6 (2.9) − 3.4 (5.5) − 1.6 (− 4.0 to 0.8) 0.1745
NRS: 0–10 PBT-IMT − 2.6 (3.1) − 2.0 (2.1) 0.6 (3.8)
Relations IMT-PBT 0.7 (2.7) 0.1 (1.9) 0.6 (3.6) − 0.4 (− 1.9 to 1.1) 0.5790
NRS: 0–10 PBT-IMT 0.0 (1.7) − 1.7 (1.3) − 1.7 (2.1)
Sleep IMT-PBT − 1.0 (2.3) 0.7 (3.0) − 1.7 (3.1) − 0.8 (− 2.5 to 0.9) 0.3279
NRS: 0–10 PBT-IMT − 1.7 (4.0) − 1.3 (2.2) 0.3 (3.9)
Enjoyment of life IMT-PBT − 0.1 (4.0) 0.0 (2.2) − 0.1 (5.1) − 0.1 (− 2.1 to 1.9) 0.9185
NRS: 0–10 PBT-IMT − 1.7 (3.2) − 1.8 (1.4) − 0.1 (3.5)
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer quality-of-life questionnaire core 30; IMT, intensity-modulated high
TENS; NRS, numerical rating scale; PBT, placebo TENS; SD, standard deviation; TENS, transcutaneous electrical nerve stimulation
NRS items adapted from the Brief Pain Inventory: 0 = no pain or no interference; 10 = worst imaginable pain or maximum interference; quality of life
scale: 1 = very poor, 7 = excellent
Sequence IMT-PBT, N = 11; sequence PBT-IMT, N = 9; total, N = 20; quality of life was measured with the EORTC QLQ-C30 quality of life item; item
“Pain relief with TENS” not listed: provides only post treatment values
*p value testing difference between treatments: paired t test of within-subject differences of pre-post change scores from both periods; p values < 0.05:
statistically significant difference between treatments (Li et al., 2015); checking carry-over effect: unpaired t test of within-subject sums of the result from
both periods: all p values were ≥ 0.05: carry-over effect is negligible (Wellek & Blettner, 2012)
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TENS. The latter could also have had a positive impact on
self-efficacy of the included cancer patients [39].
Though the washout phase of other RCTs [9–11, 31] dif-
fered from our trial, we are still confident that our study design
and its washout phase was appropriate due to the absence of
carry-over effects and washouts of 20–30 min that are consid-
ered adequate in literature [4, 40, 41].
Also, we considered methodological recommendations for
clinical trials evaluating TENS for pain treatment that covered
the domains allocation, application, and assessment [17].
Accordingly, sources of bias based on the Cochrane’s risk of
bias tool for RCTs were thoroughly considered [42].
Finally, RCT data concerning TENS from the specialist
palliative care setting is extremely scarce. Our study showed
that using TENSwas feasible in patients with advanced cancer
on an inpatient palliative care ward. It provides valuable data
on efficacy and safety, and hereby enhances the evidence base
of TENS for advanced cancer patients.
Fig. 2 Graphical analysis of pain mean intensity. a Change scores
(primary outcome). b Post treatment scores. c Change scores within
IMT. d Change scores within PBT. IMT, intensity-modulated high
TENS; NRS, numerical rating scale; PBT, placebo TENS. Negative
values in a and b favor IMT; negative values in c favor IMT or in d
PBT. Thin black line, null or no effect; dark gray line, mean of differ-
ences; light gray line, 95% confidence interval of paired t test (Li et al.,
2015)
Table 3 Change on verbal rating scale (N = 20)
Category IMT PBT
Very clear deterioration 0 (0%) 1 (5%)
Clear deterioration 0 (0%) 0 (0%)
Slight deterioration 0 (0%) 0 (0%)
No change 2 (10%) 7 (35%)
Slight improvement 13 (65%) 9 (45%)
Clear improvement 3 (15%) 1 (5%)
Very clear improvement 1 (5%) 0 (0%)
Not applicable; no pain the last 24 h 1 (5%) 2 (10%)
IMT, intensity-modulated high TENS; PBT, placebo TENS
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Limitations
A shortcoming of this study is that effects may have been
underestimated because the pain intensity was low at baseline
and outcomes were not measured during the peak effect of
TENS, i.e., immediately after stopping TENS [15]. The re-
sponder definition in this trial was pre-specified in the proto-
col (NCT02655289) and based on the VRS. However, a re-
sponder definition based on the NRS was found more appro-
priate for patients’ chronic pain conditions [43].
Most patients had some sensation during the PBT phase
and patients were told that two active TENS modes were
compared. This may have led to the considerable effects with-
in the PBT phase and, consequently, to small differences be-
tween groups. A third group, e.g., no TENS, could have been
of help for assessing the possibly large placebo effect. In gen-
eral, it should be considered that only a minority of the
screened patients on the inpatient palliative care ward was
eligible (41/632, 6.5%).
For the sake of generalizability, we included patients with
various types of cancer, sites of pain and types of pain, which
enhanced heterogeneity of the sample. In contrast to trials
assessing pain therapy in chronic non-cancer pain conditions
[44], the primary outcome in palliative cancer pain trials is
probably more influenced by progress and instability of the
disease that may have further contributed to the heterogeneity
and variance in the results.
We closely followed the study protocol (NCT02655289).
There were only two minor deviations: no block randomiza-
tion and no recruitment via palliative care consultant service
(see Online Resource 14).
We abstained from imputing missing data to enable an
intention-to-treat-analysis because of the small sample and
the pilot character of this trial [45]. Therefore, the results on
efficacy and safety of TENS for advanced cancer pain pa-
tients, and especially the subgroup analyses, need to be
interpreted cautiously and take into account that a type 2 error
cannot be excluded.
Conclusion
TENS was safe, but IMTwas unlikely to offer more analgesic
effects than PBT. As secondary outcomes, we found higher
Table 4 Change scores within
treatment IMT (N = 20) Outcome Pre mean (SD) Post mean (SD) Post–pre difference (95% CI) p value*
Average pain
NRS: 0–10
3.8 (1.0) 2.9 (1.2) − 0.9 (− 1.4 to − 0.4) 0.0027
Worst pain
NRS: 0–10
6.0 (1.7) 4.7 (2.2) − 1.3 (− 2.0 to − 0.6) 0.0010
Least pain
NRS: 0–10
2.2 (1.4) 1.5 (1.3) − 0.7 (− 1.2 to − 0.2) 0.0068
Pain relief with TENS
Scale: 0–100%
4.3 (1.5) 4.7 (0.9) 0.4 (− 0.3 to 1.0) 0.2601
Quality of life
Scale: 0–7
4.9 (1.8) 3.5 (2.4) − 1.4 (− 2.8 to 0.0) 0.0529
General activity
NRS: 0–10
4.6 (2.2) 3.7 (2.6) − 0.9 (− 2.2 to 0.4) 0.1707
Mood
NRS: 0–10
4.5 (2.6) 2.7 (2.4) − 1.8 (− 3.3 to − 0.3) 0.0206
Walking ability
NRS: 0–10
5.7 (2.3) 3.3 (2.2) − 2.4 (− 3.8 to − 1.0) 0.0017
Normal work
NRS: 0–10
2.9 (2.3) 2.6 (2.3) − 0.4 (− 1.5 to 0.8) 0.5314
Relations
NRS: 0–10
3.3 (2.5) 2.1 (2.1) − 1.2 (− 2.2 to − 0.1) 0.0310
Sleep
NRS: 0–10
4.6 (2.7) 3.7 (3.0) − 0.9 (− 2.3 to 0.6) 0.2399
EORTC QLQ-C30, European Organization for Research and Treatment of Cancer quality-of-life questionnaire
core 30; IMT, intensity-modulated high TENS; NRS, numerical rating scale; SD, standard deviation; TENS,
transcutaneous electrical nerve stimulation
NRS items adapted from the Brief Pain Inventory: 0 = no pain or no interference; 10 = worst imaginable pain or
maximum interference. Pain relief: 0% = no pain relief; 100% = maximum pain relief. Quality of life scale: 1 =
very poor, 7 = excellent
*p value of paired t test testing difference within treatment IMT
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responder rates for IMT than for PBTand mean changes with-
in both groups that may be clinically relevant for patients
especially in the IMT group. Even though many patients de-
sired to continue TENS therapy after the end of the study, 50%
of the patients still reported at least “slight pain relief” from
PBT. These results should be interpreted cautiously due to the
per-protocol analysis and the small sample size of this trial,
especially in the subgroup analyses. Nevertheless, we suggest
that differences for gender and incident pain aspects should be
further investigated in future trials.
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